logo
Plus   Neg
Share
Email

Endo International To Not Oppose Additional Stay Of FDA Litigation - Quick Facts

Endo International plc (ENDP) said Thursday that the U.S. Food and Drug Administration has requested a further stay of Endo's ongoing litigation against the FDA through March 15, 2019.

The litigation challenges the FDA's authorization of the bulk compounding of drugs, including vasopressin, that have not satisfied the legal requirements under Section 503B of the Drug Quality and Security Act amendments to the Federal Food, Drug, and Cosmetic Act.

One of Endo's subsidiaries, Par Sterile Products, LLC, manufacturers the only vasopressin product currently approved by the FDA, Vasostrict. Endo noted that the suit was most recently stayed on January 7, 2019 for the duration of the government shutdown.

However, the FDA has now filed a motion, which Endo did not oppose, seeking a further stay of the suit through March 15, 2019. In that motion, the FDA states that it "expects to publish the final clinical need determination for vasopressin on or before March 15, 2019."

Endo noted that if the FDA's motion is granted, the litigation will be stayed through March 15, 2019, subject to Endo's right to move to lift the stay in the event of a significant change in circumstances.

In October 2017, two Endo subsidiaries, Par and Endo Par Innovation Company, LLC, sued the FDA in the U.S. District Court for the District of Columbia, challenging the agency's "Interim Policy" on bulk compounding as unlawful because it authorized bulk compounding of drugs, including vasopressin, where the applicable legal requirements, including a determination of clinical need, were not satisfied.

In January 2018 and March 2018, the parties agreed to stay the case while the FDA took initial steps to comply with the statutory framework. The parties then agreed in September 2018 to another stay of the litigation based on the FDA's representation that it would use its best efforts to finalize its clinical need determination for vasopressin by December 31, 2018.

Endo said that along with other interested parties, it has submitted comments on the FDA's proposed vasopressin determination. Due to the government shutdown, however, that determination did not occur by December 31, 2018 and the litigation was stayed for the duration of the shutdown.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walmart Inc. (WMT) reported adjusted EPS of $1.41 for the fourth-quarter of fiscal 2019. On average, 27 analysts polled by Thomson Reuters expected the company to report profit per share of $1.33 for the quarter. Analysts' estimates typically exclude special items. Net income attributable to Walmart... Anglo-Australian miner BHP, formerly known as BHP Billiton, reported Tuesday higher attributable profit in its first half, while revenues were flat. Underlying EBITDA margin was lower. Further, the company maintained its dividend. Looking ahead, the company said its productivity for the 2019 financial year is now expected to be broadly flat. Asia-focused lender HSBC Holdings Plc reported Tuesday higher profit in its fiscal 2018 reflecting revenue growth in all of global businesses, despite a challenging fourth quarter. Further, the company said it reported a good start to 2019, noting that Group revenue performance in January was ahead of plan for the month. In London, HSBC shares were losing around 4 percent in the morning trading.
Follow RTT